SGEN - Why Is Cancer Focused Nurix Therapeutics Stock Trading Higher Today? | Benzinga
Nurix Therapeutics Inc (NASDAQ: NRIX) has entered into a multi-year, multi-target strategic collaboration agreement with Seagen Inc (NASDAQ: SGEN) to advance a new class of medicines called Degrader-Antibody Conjugates (DACs) for use in cancer.
The collaboration between the two companies will focus on an innovative approach to combine antibody-drug conjugation (ADC) and targeted protein degradation (TPD)—to create drugs with new mechanisms of action and improved specificity and anti-cancer activity.
Under the terms ...